Edition:
India

CSPC Pharmaceutical Group Ltd (1093.HK)

1093.HK on Hong Kong Stock

17.78HKD
19 Jan 2018
Change (% chg)

HK$0.34 (+1.95%)
Prev Close
HK$17.44
Open
HK$17.48
Day's High
HK$18.08
Day's Low
HK$17.40
Volume
18,305,860
Avg. Vol
19,081,261
52-wk High
HK$18.70
52-wk Low
HK$8.37

Select another date:

Wed, Dec 27 2017

BRIEF-CSPC Pharmaceutical Group Says Unit's Listing Application To CSRC Was Accepted

* CSPC XNW SUBMITTED APPLICATION TO CSRC FOR PROPOSED A SHARE LISTING ON CHINEXT OF SZSE & RECEIVED NOTICE OF ACCEPTANCE

BRIEF-CSPC Pharmaceutical Group Appoints ‍Li Chunlei As Executive Director ​

* ‍LI CHUNLEI WAS APPOINTED AS AN EXECUTIVE DIRECTOR OF COMPANY WITH EFFECT FROM 12 DECEMBER 2017.​

BRIEF-CSPC Pharmaceutical Group announces change of shareholdings of substantial shareholder

* ‍Massive Giant Group transferred approximately 6.78% of total issued shares to Common Success International​ Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Group posts 9-month profit attributable of HK$‍2.04​ bln

* 9-month profit attributable HK$‍2.04​ billion versus HK$1.57 billion

BRIEF-CSPC Pharmaceutical Group updates on approvals ​of granted clinical trial

* Group's "HA121-28" and "alprostadil liposome injection" were granted clinical trial approvals ​

BRIEF-CSPC Pharmaceutical Group ‍to issue 189 mln placing shares at HK$12.44 per share​

* ‍shall issue 189 million placing shares at placing price of hk$12.44 per share​

BRIEF-CSPC Pharmaceutical Group updates on trading halt

* ‍seeks trading halt pending release of announcement regarding placing of new shares under general mandate​ Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical says‍ trading in shares of co has been halted

* ‍Trading in shares of co has been halted at 9:08 a.m. on oct 12 Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Group's unit buys 1.31 PCT stake in CSPC Innovation Pharmaceutical

* Unit announces ‍acquisition of 1.31 percent stake in CSPC Innovation Pharmaceutical Co for RMB 9.4 million

BRIEF-CSPC Pharmaceutical Group receives U.S.FDA orphan-drug designation for malignant tumour treatment drug

* Group's Malignant Tumour Treatment Drug "Mitoxantrone Hydrochloride Liposome' was granted orphan-drug designation by the U.S. FDA

Select another date: